Starting Tuesday, March 26, MHC will convert to Tenecteplase as its dedicated thrombolytic therapy of choice for Acute Ischemic Stroke (AIS). This decision was made as it shortens treatment times for patients and is easier for staff to administer.
-
Clinical outcome data supports Tenecteplase use for AIS patients and is fully supported by MMC’s Comprehensive Stroke Program leadership.
-
Tenecteplase will follow the same exact inclusion/exclusion criteria currently used for Alteplase and be delivered at a dose of 0.25mg/kg (max dose of 25mg). Look for updated stroke protocol packets, including the increased monitoring required by nurses for signs and symptoms of angioedema with Tenecteplase.
Cerner: Effective Tuesday, March 26, all Ischemic Stroke PowerPlans and reference texts with Alteplase or tPA verbiage will be updated with new Tenecteplase verbiage.
Questions? Contact Clinical Pharmacist Philip Dimondo.